Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Injectable Agent Makes Cancerous Cells Visible During Surgery

By HospiMedica International staff writers
Posted on 01 Feb 2016
Results from a trial published on January 6, 2015, in the journal Science Translational Medicine show how a new injectable agent can be used during soft-tissue sarcoma or breast cancer surgery to identified remnants of cancerous tissue.

Cancer surgeons use Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans as guides during excision of tumors and surrounding tissue, however traces of cancerous tissue around the tumor remain undetected and as a result are not removed, leading to additional surgery later, and radiation therapy.

The trial was carried out at Duke University Medical Center (Durham NC, USA) and included 15 patients undergoing surgery for soft-tissue sarcoma or breast cancer. More...
The researchers tested the new injectable agent called LUM015 that makes tumor cells visible by causing fluorescence, and enables surgeons to find and take out all cancerous tissue in one operation.

The research into the new imaging technology was made possible by a collaboration between scientists at Duke University Medical Center, Massachusetts Institute of Technology (MIT; Cambridge, MA, USA), and a company called Lumicell (Wellesley, MA, USA).

As a next step, researchers at Massachusetts General Hospital are evaluating the efficacy and safety of LUM015 and the imaging technology in a trial with 50 women suffering from breast cancer. After that, the researchers plan to verify that the technology can reduce the number of second operations following surgery for the removal of breast cancer.

David Kirsch, MD, PhD, professor at Duke University School of Medicine, and senior author of the study, said. “At the time of surgery, a pathologist can examine the tissue for cancer cells at the edge of the tumor using a microscope, but because of the size of cancer it’s impossible to review the entire surface during surgery. The goal is to give surgeons a practical and quick technology that allows them to scan the tumor bed during surgery to look for any residual fluorescence.”

Related Links:

Duke University Medical Center
Massachusetts General Hospital
Lumicell



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.